Results 121 to 130 of about 760 (154)
Durlobactam in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections: A Systematic Review [PDF]
Journal of Clinical Medicine, 2022 A. baumannii is a frequent cause of difficult-to-treat healthcare-associated infections. The use of a novel beta-lactamase inhibitor, durlobactam, has been proposed against multidrug-resistant A. baumannii. A systematic review of studies assessing the efficacy and safety of durlobactam in the treatment of multidrug-resistant A. baumannii infections was
Guido Granata +2 more
exaly +8 more sources
Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic Review [PDF]
Antibiotics, 2022 Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) have limited therapeutic options. Sulbactam-durlobactam is a combination of two βlactamase inhibitors with activity against CRAB under phase 3 clinical investigation. We performed a systematic review on in vitro studies reporting A.
Stefano Di Bella +2 more
exaly +7 more sources
Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece [PDF]
Frontiers in Cellular and Infection Microbiology, 2022 Background: Acinetobacter baumannii is a leading cause of healthcare-associated infections worldwide, due to both its persistence in the hospital setting and ability to acquire high levels of antibiotic resistance. Carbapenem-resistant A.
Maria Siopi +2 more
exaly +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections
Annals of Pharmacotherapy, 2023Objective: To review the pharmacology, efficacy, and safety of intravenous sulbactam-durlobactam (SUL-DUR) in the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Data Sources: PubMed databases and ...
Benjamin August +2 more
openaire +2 more sources
Sulbactam/Durlobactam (Xacduro) for Acinetobacter Pneumonia
The Medical Letter on Drugs and Therapeutics, 2023The FDA has approved Xacduro (Innoviva), a combination of the beta-lactam antibacterial sulbactam and the beta-lactamase inhibitor durlobactam, for IV treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (ABC).
openaire +2 more sources
Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex
Expert Review of Anti-Infective TherapyInfections with Acinetobacter baumannii-calcoaceticus complex (ABC) pose difficulty for clinicians given a limited arsenal of effective antimicrobials. Sulbactam/durlobactam provides a novel treatment option for patients experiencing hospital- or ventilator-acquired pneumonia with susceptible strains.This review provides a comprehensive discussion of ...
Anthony Guarascio, Jordan Covvey
exaly +3 more sources
American Journal of Health-System Pharmacy, 2023
Abstract Purpose Sulbactam/durlobactam is a combination antibiotic designed to target Acinetobacter baumannii, including carbapenem-resistant and multidrug-resistant strains. The objective of this study was to determine the physical compatibility of sulbactam/durlobactam solution during simulated Y ...
Victor H, Ruiz +5 more
openaire +2 more sources
Abstract Purpose Sulbactam/durlobactam is a combination antibiotic designed to target Acinetobacter baumannii, including carbapenem-resistant and multidrug-resistant strains. The objective of this study was to determine the physical compatibility of sulbactam/durlobactam solution during simulated Y ...
Victor H, Ruiz +5 more
openaire +2 more sources
Clinical Infectious Diseases
Abstract Background The treatment of carbapenem-resistant Acinetobacter baumannii/calcoaceticus complex (CRAB) presents significant treatment challenges. Methods We report the case of a 42-year-old woman with CRAB meningitis who ...
Pranita D Tamma +10 more
openaire +2 more sources
Abstract Background The treatment of carbapenem-resistant Acinetobacter baumannii/calcoaceticus complex (CRAB) presents significant treatment challenges. Methods We report the case of a 42-year-old woman with CRAB meningitis who ...
Pranita D Tamma +10 more
openaire +2 more sources
International Journal of Antimicrobial Agents
The broth microdilution method was used as a reference method to evaluate the accuracy of sulbactam-durlobactam disk diffusion method for A. baumannii.In 2023, 504 nonduplicated A. baumannii isolated from 59 hospitals in China were tested by broth microdilution (M07) and disk diffusion method (M02) (10/10 µg) according to the CLSI M100 Ed34 standard ...
Xiaolan Hong +7 more
openaire +2 more sources
The broth microdilution method was used as a reference method to evaluate the accuracy of sulbactam-durlobactam disk diffusion method for A. baumannii.In 2023, 504 nonduplicated A. baumannii isolated from 59 hospitals in China were tested by broth microdilution (M07) and disk diffusion method (M02) (10/10 µg) according to the CLSI M100 Ed34 standard ...
Xiaolan Hong +7 more
openaire +2 more sources
Sulbactam–durlobactam for Acinetobacter pneumonia
The Lancet Infectious Diseases, 2023Ammara Mushtaq, Abhinandan Anand Raman
openaire +1 more source